Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Am J Transplant. 2012 Aug 6;12(11):2920–2929. doi: 10.1111/j.1600-6143.2012.04203.x

FIG. 2. Graft protection by ECDI-SPs treatment is concomitant with intra-graft IDO-expressing cells.

FIG. 2

A: Graft histology showing immunohistochemical staining of IDO+ cells. Magnification: x10. Data shown is representative of at least three cardiac grafts obtained and sectioned from each treatment group on post transplant day 7. B: Spleen histology showing immunohistochemical staining of IDO+ cells. Magnification: x20. Data shown is representative of two spleens obtained and sectioned from each treatment group on post transplant day 7. Bar graphs show average cell numbers per high power field counted from 10–12 different sections of two different spleens from each group. C: Effect of the IDO inhibitor 1-MT on cardiac graft protection by ECDI-SPs treatment alone or ECDI-SPs treatment in combination with rapamycin. 1-MT was given at 10 mg/day i.p. from day −7 to day +7 as described in Materials and Methods. D: Dual staining of cardiac grafts with CD11b (blue) and IDO (brown). Magnification: x100. Data shown is from a cardiac graft from the ECDI-SPs alone treatment group, but is representative of 3 cardiac grafts each obtained and sectioned from the ECDI-SPs alone or ECDI-SPs + rapamycin treatment groups.